The CAR T-cell therapy market size was estimated at US$ 2.20 billion in 2022 it is predicted to grow at a CAGR of 11.4% from 2023 to 2032 to reach around US$ 6.48 billion by the end of 2032.
The CAR T-cell therapy market report offers an exclusive study of the present state expected at the market dynamics, opportunities, market scheme, growth analysis and regional outlook. The report presents energetic visions to conclude and study the market size, market aspiration, and competitive environment. The research also focuses on the important achievements of the market, research & development, and regional (country by country) growth of the leading vendors operating in the market
The study offers intricate dynamics about different aspects of the global CAR T-cell therapy market, which aids companies operating in the market in making strategies development decisions. The study also elaborates on remarkable changes that are highly anticipated to configure growth of the global CAR T-cell therapy market during the forecast period. It also includes a key indicator analysis that highlights growth prospects of this market and approximate statistics related to growth of the market in terms of value (US$ Bn) and volume (tons).
Sample Link @ https://www.visionresearchreports.com/report/sample/40008
Market Scope
| Report Coverage | Details |
| Market Size in 2022 | USD 2.20 billion |
| Revenue Forecast by 2032 | USD 6.48 billion |
| Growth rate from 2023 to 2032 | CAGR of 11.4% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | Kolon TissueGene, Inc.; JCR Pharmaceuticals Co., Ltd.; MEDIPOST; PHARMICELL Co., Ltd.; ANTEROGEN. CO., LTD; Bristol-Myers Squibb Company; Novartis AG; Gilead Sciences, Inc.; Curocell, Inc.; JW Therapeutics (Shanghai) Co., Ltd.; Stempeutics Research PVT LTD |
This study covers an elaborate segmentation of the global CAR T-cell therapy market, along with important information and a competition outlook. The report mentions company profiles of players that are currently influence the global CAR T-cell therapy market, wherein various developments, expansions, and winning strategies practiced and execute by leading players have been presented in detail.
CAR T-Cell Therapy Market Segmentations:
| By Drug Type | By Indication | By End User |
| Axicabtagene Ciloleucel
Tisagenlecleucel Brexucabtagene Autoleucel Others |
Lymphoma
Acute Lymphocytic Leukemia Chronic Lymphocytic Leukemia (CLL) Multiple Myeloma (MM) Others |
Hospitals
Cancer Treatment Centers |
Research Methodology
The research methodology acquire by analysts for assemble the global CAR T-cell therapy market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts study numerous annual report declaration, white papers, market association declaration, and company websites to obtain the necessary understanding of the global CAR T-cell therapy market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on CAR T-Cell Therapy Market
5.1. COVID-19 Landscape: CAR T-Cell Therapy Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global CAR T-Cell Therapy Market, By Drug Type
8.1. CAR T-Cell Therapy Market, by Drug Type, 2023-2032
8.1.1 Axicabtagene Ciloleucel
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Tisagenlecleucel
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Brexucabtagene Autoleucel
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global CAR T-Cell Therapy Market, By Indication
9.1. CAR T-Cell Therapy Market, by Indication, 2023-2032
9.1.1. Lymphoma
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Acute Lymphocytic Leukemia
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Chronic Lymphocytic Leukemia (CLL)
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Multiple Myeloma (MM)
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global CAR T-Cell Therapy Market, By End User
10.1. CAR T-Cell Therapy Market, by End User, 2023-2032
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Cancer Treatment Centers
10.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global CAR T-Cell Therapy Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.1.2. Market Revenue and Forecast, by Indication (2020-2032)
11.1.3. Market Revenue and Forecast, by End User (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.1.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.1.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.2.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.3. Market Revenue and Forecast, by End User (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.6.3. Market Revenue and Forecast, by End User (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.7.3. Market Revenue and Forecast, by End User (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.3.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.3. Market Revenue and Forecast, by End User (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.6.3. Market Revenue and Forecast, by End User (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.7.3. Market Revenue and Forecast, by End User (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.6.3. Market Revenue and Forecast, by End User (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.7.3. Market Revenue and Forecast, by End User (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.5.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.5.5.3. Market Revenue and Forecast, by End User (2020-2032)
Chapter 12. Company Profiles
12.1. Kolon TissueGene, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. JCR Pharmaceuticals Co., Ltd.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Kolon TissueGene, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. JCR Pharmaceuticals Co., Ltd.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. MEDIPOST
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. PHARMICELL Co., Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. ANTEROGEN. CO., LTD
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bristol-Myers Squibb Company
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Novartis AG
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Gilead Sciences, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Vision Research Reports
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168